March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Cumulative Incidence of Visual Acuity Change in the VIEW 1 and VIEW 2 Studies of Patients with Neovascular Age-related Macular Degeneration
Author Affiliations & Notes
  • Daniel B. Roth
    Ophthalmology, Robert Wood Johnson Med School, New Brunswick, New Jersey
  • Jeffrey S. Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts
  • Desmond Thompson
    Regeneron, Tarrytown, New York
  • Yuhwen Soo
    Regeneron, Tarrytown, New York
  • Robert Vitti
    Regeneron, Tarrytown, New York
  • Namrata Saroj
    Regeneron, Tarrytown, New York
  • Alyson J. Berliner
    Regeneron, Tarrytown, New York
  • Georg Groeztbach
    Regeneron, Tarrytown, New York
  • Olaf Sowade
    Bayer HealthCare Pharmaceuticals, Berlin, Germany
  • Oliver Zeitz
    Global Clinical Development, Bayer HealthCare AG, Berlin, Germany
  • Footnotes
    Commercial Relationships  Daniel B. Roth, Allergan Genentech, QLT, Regeneron (C); Jeffrey S. Heier, Allergan (C), Genentech (C), Regeneron (C); Desmond Thompson, Regeneron (E); Yuhwen Soo, Regeneron (E); Robert Vitti, Regeneron (E); Namrata Saroj, Regeneron (E); Alyson J. Berliner, Regneron (E); Georg Groeztbach, Bayer HealthCare (E); Olaf Sowade, Bayer HealthCare (E); Oliver Zeitz, Bayer HealthCare Pharmceuticals (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2042. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Daniel B. Roth, Jeffrey S. Heier, Desmond Thompson, Yuhwen Soo, Robert Vitti, Namrata Saroj, Alyson J. Berliner, Georg Groeztbach, Olaf Sowade, Oliver Zeitz; Cumulative Incidence of Visual Acuity Change in the VIEW 1 and VIEW 2 Studies of Patients with Neovascular Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2042.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To test the hypothesis that the time to sustained visual acuity gain or loss in wet AMD patients is similar among different dosing regimens of intravitreal aflibercept injection (IAI; also referred to as VEGF Trap-Eye), including every-two-month dosing, and monthly ranibizumab.


A total of 2457 patients with AMD from VIEW 1 and VIEW 2 were randomized to four treatment groups: ranibizumab 0.5 mg every 4 weeks (Rq4wk), IAI 2 mg every 4 weeks (2q4wk), 0.5 mg every 4 weeks (0.5q4wk), and 2 mg every 8 weeks (2q8wk, after 3 initial monthly doses). In this study, the pre-specified analysis assessed the temporal pattern of the cumulative incidence of the following events: first gain or loss of ≥15 letters (simple event) and first ≥2 consecutive occurrences gain or loss of ≥15 letters (sustained event). Kaplan-Meier methodology was used to compare the cumulative incidence curves for the treatment groups. The analysis was adjusted for varying patterns of censorship.


Outcomes for ≥15 letters at Week 52 are shown in the table.Cumulative incidence curves did not differ among the four dosing regimens for the two anti-VEGF agents: P=0.69, P=0.75, P=0.92 and P=0.92 for the respective outcomes listed in the first column of the table. Improvement in vision was observed early in all treatment groups.


Temporal patterns in visual acuity gain or loss were similar among all treatment groups, indicating that the every-two-months treatment with intravitreal aflibercept injection was as beneficial as monthly doses of intravitreal aflibercept injection or ranibizumab.  

Clinical Trial: NCT00509795

Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • vascular endothelial growth factor 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.